Ved pneumoni er der påvist effekt hos et begrænset antal patienter med risikofaktorer såsom pneumococ bacteriæmi eller alder mere end 65 år.
In community acquired pneumonia, efficacy has been demonstrated in a limited number of patients with risk factors such as pneumococcal bacteraemia or age higher than 65 years.